SMS Pharmaceuticals has received a non?exclusive license through the Medicines Patent Pool (MPP) to manufacture molnupiravir, an investigational oral antiviral COVID?19 medicine, to increase broad access of treatment in 105 low? and middle? income countries (LMIC).
MSD, a trade name of Merck & Co., Inc, Kenilworth, NJ, USA., has entered into an agreement to license this pill for wider distribution with patent group. Under the terms of the agreement, MPP, through the license granted by MSD, will be permitted to further license non? exclusive sublicences to manufacturers and diversify the manufacturing base for the supply of molnupiravir to countries covered by the MPP Licence, subject to local regulatory authorization.
SMS Pharmaceuticals is a global player in API and intermediates manufacturing having a strong research and manufacturing team supported by state?of?the?art facilities.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: